Gynecologic Oncology at Fudan University Shanghai Cancer Center | CMCS

Expert Gynecologic Cancer Care at China's Premier Cancer Center

The Department of Gynecologic Oncology at Fudan University Shanghai Cancer Center (FUSCC) is one of China's most distinguished centers for the surgical and medical management of gynecologic cancers, with a national reputation for excellence in the treatment of cervical cancer, ovarian cancer, endometrial cancer, vulvar cancer, and rare gynecologic malignancies. The department combines outstanding surgical expertise with a world-class research program and a fully integrated multidisciplinary approach, offering international patients access to the latest evidence-based treatments and clinical trials for all stages of gynecologic cancer.

For international patients with gynecologic cancer — whether seeking surgical treatment, a second opinion, access to PARP inhibitors or immunotherapy, or expert management of a recurrent or rare gynecologic tumor — FUSCC's gynecologic oncology department offers an unparalleled combination of expertise, volume, and research leadership. China Medical Concierge Shanghai (CMCS) provides seamless end-to-end coordination for international patients throughout their care journey at FUSCC.

About the Department

FUSCC's gynecologic oncology department is a national key clinical specialty performing thousands of gynecologic cancer operations annually. The department operates dedicated gynecologic oncology wards, a comprehensive outpatient gynecologic oncology clinic, a gynecologic cancer MDT, a minimally invasive and robotic gynecologic surgery program, and works in close collaboration with radiation oncology, medical oncology, pathology, radiology, and nuclear medicine through a fully integrated multidisciplinary team.

Faculty members publish regularly in leading gynecologic oncology journals including Journal of Clinical Oncology, Annals of Oncology, Gynecologic Oncology, International Journal of Gynecological Cancer, and Cancer.

Conditions Treated

Cervical Cancer

• Early-Stage Cervical Cancer (Stage IA-IB1) — Fertility-sparing radical trachelectomy (abdominal and vaginal) for young patients wishing to preserve fertility; radical hysterectomy with pelvic lymph node dissection; minimally invasive approaches
• Locally Advanced Cervical Cancer (Stage IB2-IVA) — Concurrent chemoradiation (cisplatin + IMRT/brachytherapy); induction chemotherapy for bulky disease; pembrolizumab + chemoradiation for PD-L1-positive disease
• Recurrent & Metastatic Cervical Cancer — Pembrolizumab + chemotherapy ± bevacizumab (KEYNOTE-826); tisotumab vedotin for recurrent disease; pelvic exenteration for selected central recurrences
• Cervical Adenocarcinoma — Surgical management; adjuvant therapy based on risk factors
• Cervical Neuroendocrine Carcinoma — Multimodality treatment with platinum-etoposide chemotherapy
• CIN & Precancerous Lesions — LEEP, cold knife conization, and surveillance

Ovarian Cancer

• Epithelial Ovarian Cancer — Primary debulking surgery (PDS) aiming for complete cytoreduction (R0); interval debulking surgery (IDS) after neoadjuvant chemotherapy for initially unresectable disease; carboplatin + paclitaxel ± bevacizumab; PARP inhibitors (olaparib, niraparib, rucaparib) for maintenance therapy in BRCA-mutated and HRD-positive disease
• BRCA1/2-Mutated Ovarian Cancer — Olaparib maintenance after first-line platinum-based chemotherapy; olaparib + bevacizumab for HRD-positive disease; genetic counseling and family testing
• Platinum-Sensitive Recurrent Ovarian Cancer — Re-challenge with platinum-based chemotherapy; PARP inhibitor maintenance; secondary cytoreductive surgery for selected patients
• Platinum-Resistant Ovarian Cancer — Pegylated liposomal doxorubicin, gemcitabine, topotecan; mirvetuximab soravtansine for FRα-positive disease; clinical trial access
• Low-Grade Serous Ovarian Cancer — MEK inhibitors (trametinib, binimetinib); letrozole; surgical cytoreduction
• Clear Cell Ovarian Cancer — Platinum-based chemotherapy; immunotherapy combinations; clinical trials
• Mucinous Ovarian Cancer — FOLFOX/FOLFIRI-based chemotherapy; bevacizumab
• Borderline Ovarian Tumors — Fertility-sparing surgery; surveillance
• Ovarian Germ Cell Tumors — BEP chemotherapy; fertility preservation
• Sex Cord-Stromal Tumors — Surgical management; hormonal therapy for granulosa cell tumors

Endometrial Cancer

• Early-Stage Endometrial Cancer (Stage I-II) — Minimally invasive total hysterectomy with bilateral salpingo-oophorectomy and sentinel lymph node mapping; robotic-assisted surgery; fertility-sparing management with progestins for selected young patients with grade 1 endometrioid cancer
• Advanced Endometrial Cancer (Stage III-IV) — Surgical cytoreduction; carboplatin + paclitaxel; pembrolizumab + chemotherapy for dMMR/MSI-H disease (KEYNOTE-868); dostarlimab + chemotherapy; lenvatinib + pembrolizumab for pMMR disease
• Recurrent Endometrial Cancer — Pembrolizumab for dMMR/MSI-H; lenvatinib + pembrolizumab for pMMR; hormonal therapy for low-grade recurrence
• Uterine Serous Carcinoma — Carboplatin + paclitaxel + trastuzumab for HER2-positive disease; pembrolizumab combinations
• Uterine Carcinosarcoma — Carboplatin + paclitaxel; pembrolizumab
• Endometrial Stromal Sarcoma — Hormonal therapy for low-grade ESS; chemotherapy for high-grade ESS; pazopanib
• Uterine Leiomyosarcoma — Gemcitabine + docetaxel; doxorubicin; trabectedin; pazopanib

Vulvar & Vaginal Cancer

• Vulvar Squamous Cell Carcinoma — Wide local excision with sentinel lymph node biopsy for early disease; radical vulvectomy with inguinofemoral lymph node dissection for advanced disease; chemoradiation for unresectable disease; pembrolizumab for recurrent/metastatic disease
• Vulvar Melanoma — Wide local excision; BRAF/MEK inhibitors and PD-1 immunotherapy for advanced disease
• Vaginal Cancer — Radiation therapy; surgical management for selected early cases
• Vulvar Intraepithelial Neoplasia (VIN) — Imiquimod, sinecatechins, and surgical excision

Gestational Trophoblastic Disease

• Hydatidiform Mole — Suction curettage; hCG surveillance; prophylactic chemotherapy for high-risk moles
• Gestational Trophoblastic Neoplasia (GTN) — Single-agent methotrexate or actinomycin D for low-risk GTN; EMA-CO for high-risk GTN; salvage chemotherapy for refractory disease; fertility preservation

Rare Gynecologic Tumors

• Primary Peritoneal Cancer — Managed as ovarian cancer; CRS-HIPEC for selected patients
• Fallopian Tube Cancer — Surgical staging and platinum-based chemotherapy
• Small Cell Carcinoma of the Ovary (Hypercalcemic Type) — SMARCA4 mutation-targeted therapy; clinical trials

Surgical Excellence

Minimally Invasive & Robotic Gynecologic Oncology Surgery

FUSCC's gynecologic oncology department has been at the forefront of minimally invasive surgery adoption in China, offering:

• Robotic-Assisted Hysterectomy & Staging — da Vinci robotic total hysterectomy with pelvic and para-aortic lymph node dissection for endometrial cancer; enhanced precision for obese patients and narrow pelvis
• Laparoscopic Radical Hysterectomy — For selected early-stage cervical cancer; careful patient selection based on tumor size and histology
• Laparoscopic Ovarian Cancer Staging — Comprehensive laparoscopic staging for apparent early-stage ovarian cancer
• Sentinel Lymph Node Mapping — ICG fluorescence-guided sentinel lymph node biopsy for endometrial and cervical cancer; reducing lymphedema risk

Fertility-Sparing Surgery

For young patients with early-stage gynecologic cancers who wish to preserve fertility, FUSCC offers:

• Radical Trachelectomy — Abdominal and vaginal radical trachelectomy for early cervical cancer; preservation of the uterine body for future pregnancy
• Conservative Management of Endometrial Cancer — Progestin therapy with hysteroscopic surveillance for grade 1 endometrioid cancer in young patients
• Fertility-Sparing Ovarian Surgery — Unilateral salpingo-oophorectomy for early-stage ovarian cancer and borderline tumors in young patients

Cytoreductive Surgery & HIPEC

For selected patients with peritoneal metastases from ovarian, primary peritoneal, or fallopian tube cancer, FUSCC offers cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) — a complex procedure that removes all visible peritoneal disease followed by heated intraperitoneal chemotherapy to eliminate microscopic residual disease.

PARP Inhibitor Program

FUSCC's gynecologic oncology department has extensive experience with PARP inhibitors — the most significant advance in ovarian cancer treatment in decades:

• BRCA Testing — Germline and somatic BRCA1/2 testing for all ovarian cancer patients; HRD testing (myChoice CDx) for maintenance therapy eligibility
• Olaparib — First-line maintenance for BRCA-mutated advanced ovarian cancer; olaparib + bevacizumab for HRD-positive disease
• Niraparib — First-line maintenance regardless of BRCA/HRD status; individualized starting dose based on body weight and platelet count
• Rucaparib — For BRCA-mutated recurrent ovarian cancer
• Mirvetuximab Soravtansine — FRα-targeted ADC for platinum-resistant FRα-high ovarian cancer

Why International Patients Choose FUSCC Gynecologic Oncology

• National Leadership — One of China's highest-volume and most distinguished gynecologic oncology programs
• PARP Inhibitor Expertise — Comprehensive BRCA/HRD testing and PARP inhibitor maintenance program for ovarian cancer
• Fertility-Sparing Surgery — Radical trachelectomy and conservative endometrial cancer management for young patients
• Immunotherapy Integration — Pembrolizumab combinations for cervical, endometrial, and ovarian cancer
• Clinical Trial Access — Active participation in trials for novel targeted and immunotherapy agents for gynecologic cancers
• Cost-Effectiveness — World-class gynecologic cancer care at significantly lower cost than equivalent treatment in Western countries

The CMCS Patient Journey

1. Initial Inquiry — Share your diagnosis, imaging (CT, MRI, PET-CT), biopsy pathology, molecular profiling (BRCA, HRD, MSI, HER2), and prior treatment history with CMCS.
2. Medical Record Preparation — We translate and organize your records for specialist pre-consultation review.
3. Specialist Matching — We identify the most appropriate gynecologic oncologist based on your tumor type — cervical, ovarian, endometrial, or rare gynecologic cancer.
4. MDT Submission — Where appropriate, we facilitate pre-arrival case review by FUSCC's gynecologic oncology MDT.
5. Priority Scheduling — We secure a consultation and surgical slot with minimal waiting time.
6. Travel & Logistics — Assistance with visa invitation letters, accommodation near FUSCC, and Shanghai airport transfers.
7. Surgical Admission Support — Full coordination of pre-operative assessment, neoadjuvant therapy scheduling if required, admission, and inpatient care.
8. Post-Operative Follow-Up — Pathology report translation, adjuvant therapy coordination, and remote follow-up after you return home.

Book a Consultation

If you are seeking expert gynecologic cancer care in Shanghai — whether for cervical cancer, ovarian cancer, endometrial cancer, vulvar cancer, or a rare gynecologic malignancy — CMCS can arrange a specialist consultation with FUSCC's gynecologic oncology team.

📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com